Small Molecule Compounds Modulating Ferroptosis for RAS-Mutant Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to selectively target and destroy RAS-mutant tumor cells and manage ferroptosis, a unique form of iron-dependent cell death, which is distinct from apoptosis and necrosis, and is associated with increased reactive oxygen species (ROS) levels.
Innovation Solution
Development of small molecule compounds, such as erastin and its analogs, which inhibit ferroptosis by targeting specific pathways, including the use of ferrostatins that modulate ferroptosis to selectively kill RAS-mutant tumor cells or protect neuronal cells from oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target tumor cells, then general cell death pathways (apoptosis, necrosis) are activated, but ferroptosis - a selective iron-dependent cell death pathway - cannot be effectively triggered in RAS-mutant tumor cells
Solution Approach 1:
The patent converts the harmful accumulation of iron and reactive oxygen species (ROS) in RAS-mutant tumor cells into a beneficial therapeutic effect by triggering ferroptosis. RSL compounds exploit the existing iron overload and oxidative stress in these cancer cells, transforming what would normally be damaging factors into selective killers that induce iron-dependent lipid peroxidation and cell death specifically in RAS-mutant cells while sparing normal cells.
2Object-affected harmful factors
If iron chelation or genetic inhibition of cellular iron uptake is used to prevent ferroptosis, then ferroptosis is blocked, but this approach lacks specificity for RAS-mutant tumor cells
Solution Approach 1:
The patent introduces small molecule compounds (RSL compounds, ferrostatins) as intermediaries that mediate the triggering or inhibition of ferroptosis. These small molecules act as convenient chemical tools that can specifically modulate the ferroptosis pathway - RSL compounds trigger it by inhibiting system Xc- and promoting iron accumulation, while ferrostatins inhibit it by scavenging lipid peroxides - providing a simpler alternative to complex genetic interventions.
3Productivity
If RSL compounds are used to trigger ferroptosis, then selective killing of RAS-mutant tumor cells is achieved, but the mechanism of action remains enigmatic and difficult to control
Solution Approach 1:
The patent segments the complex ferroptosis mechanism into distinct, controllable components: (1) RSL compounds that specifically inhibit system Xc- to trigger iron accumulation and ROS production, (2) downstream effectors including iron-dependent lipid peroxidation pathways, and (3) regulatory elements such as ferrostatins that can specifically inhibit the lethal process. This segmentation allows researchers to study and control different aspects of ferroptosis independently, transforming the enigmatic mechanism into a tractable therapeutic pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively prevent ferroptosis in cancer cells and neuronal cells, offering a potential therapeutic approach for treating cancers and neurodegenerative diseases by selectively targeting and destroying RAS-mutant tumor cells while reducing ROS levels.
Implementation Method 1
RSL-induced death is, however, associated with increased levels of intracellular reactive oxygen species (ROS) and is prevented by iron chelation or genetic inhibition of cellular iron uptake
Implementation Method 2
The type of cell death activated by the RSLs has been enigmatic... RSL-induced death is, however, associated with increased levels of intracellular reactive oxygen species (ROS)... the prevention of cell death by iron chelation was a rare phenomenon
Data Source
AI summary
The present disclosure provides, inter alia, a compound having the structure:Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.